Investing for a Greener Future in Pharma

What will this webinar address?

The EU Green Taxonomy is currently being rolled out, and it aims to define which of a company’s activities are ‘green’, thereby making it easier for financial companies to funnel capital towards green companies/projects while minimizing their risks of greenwashing. The European Commission is expected to adopt that will introduce criteria for pharmaceutical companies to be considered "environmentally sustainable" and will come into play in 2024. What more can be done

The idea is a good one – but how is the implementation going in practice and what does Pharma need to know?

To gain deeper insights, we invite you to our upcoming CPHI webinar. During this session, listen to our experts to explore the most recent developments in green taxonomy, as well as the strategies for achieving industry-wide sustainability goals and enhancing investment prospects for the most environmentally responsible companies.

• Breaking down the purpose of EU green taxonomy and its connections to other EU regulations
• Updating on the Environmental Delegates Act (EDA)
• What can pharma do align their current activities to meet green taxonomy